Cover Image
Market Research Report

Coronavirus Disease 2019 (COVID-19) Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H1 2020

Published by GervanoRA Data Services LLP Product code 940538
Published Content info 255 Pages
Delivery time: 1-2 business days
Price
Back to Top
Coronavirus Disease 2019 (COVID-19) Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H1 2020
Published: June 6, 2020 Content info: 255 Pages
Description

GervanoRA's pipeline analysis and opportunity assessment report "Coronavirus Disease 2019 (COVID-19) Pipeline Drugs - Opportunity Assessments, Epidemiological Studies, Market Dynamics and Pipeline Analytics H1 2020" analysed and assessed Coronavirus Disease 2019 (COVID-19) pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in COVID-19 therapeutics industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the COVID-19 disease area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in COVID-19 drugs and vaccines industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type. The report has also highlighted the universities and institutes working on the development of new innovative therapeutics for the treatment of COVID-19.

Our comprehensive analysis on the COVID-19 therapeutic pipeline identified 322 therapeutic candidates (drugs and vaccines) undergoing different stages of development- from Early R&D to Phase 3 stage. Among these, 146 therapeutics are in clinical stages of development and a total of 161 molecules are in non-clinical stage of development. The drug pipeline consists of 151 preclinical drug candidates and 10 molecules still in their early stages of discovery.

The report has covered more than 310 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Drivers and Restraints
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analytics of Pipeline Molecules
  • Pipeline Analysis of all Drug Molecules and Vaccines
  • Estimated Pipeline Drug Approval Time lines of Late Clinical Stage (Phase 3) Pipeline Drug Candidates
  • Estimated Approval Time lines of all Vaccines Under Development
  • Clinical Stage Drug Candidates' Descriptions along with Development Milestones
  • Opportunity Assessments through Competitive Benchmarking
  • Evaluate Current and Future Competitive Landscape through Company Profiles
  • Emerging Company Profiles with Opportunity Assessments

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

Table of Contents
Product Code: GERPH1098

TABLE OF CONTENTS

CHAPTER 01: INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. ABOUT US: GERVANORA DATA SERVICES

CHAPTER 02: EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN THE COVID-19 COMPETITIVE SPACE
  • 2.3. REPORT MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS

CHAPTER 03: CORONAVIRUS DISEASE 2019 (COVID-19) OVERVIEW

  • 3.1. DISEASE DEFINITION AND SYMPTOMS
  • 3.2. DISEASE CAUSE AND CLASSIFICATION
  • 3.3. DISEASE DIAGNOSIS
  • 3.4. AVAILABLE TREATMENTS AND GUIDELINES
  • 3.5. EPIDEMIOLOGICAL STUDIES

CHAPTER 04: MARKET DYNAMICS OF COVID-19 COMPETITIVE SPACE

  • 4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)
    • 4.1.1 DEALS ANALYTICS BY DEAL TYPE
      • 4.1.1.1. COLLABORATION DEALS
      • 4.1.1.2. FINANCING DEALS
      • 4.1.1.3. LICENSING DEALS
      • 4.1.1.4. MERGER AND ACQUISITION DEALS
    • 4.1.2 DEALS ANALYTICS BY MONTHLY FREQUENCY
    • 4.1.3 DEALS ANALYTICS BY ACTIVE PLAYER
  • 4.2. PATENT ANALYSIS (EXPIRIES AND GENERICIZATION)
    • 4.2.1. PATENT ANALYTICS OF PIPELINE DRUGS

CHAPTER 05: PIPELINE DRUGS ANALYTICS OF CORONAVIRUS DISEASE 2019 (COVID-19)

  • 5.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • 5.1.1. PHASE III PIPELINE THERAPIES
    • 5.1.2. PHASE II PIPELINE THERAPIES
    • 5.1.3. PHASE I PIPELINE THERAPIES
    • 5.1.4. PRECLINICAL PIPELINE THERAPIES
    • 5.1.5. EARLY R&D PIPELINE THERAPIES
  • 5.2. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION
    • PIPELINE ANALYTICS BY PARENTERALS AS ROUTE OF ADMINISTRATION
    • PARENTERAL PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
    • PIPELINE ANALYTICS BY ORAL AS ROUTE OF ADMINISTRATION
    • ORAL PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT
  • 5.3. PIPELINE DRUGS ANALYTICS BY DRUG CLASS
    • ANTIVIRAL THERAPEUTICS PIPELINE DRUGS ANALYTICS
    • ANTIBODY-BASED THERAPEUTICS PIPELINE DRUGS ANALYTICS
    • SMALL MOLECULE THERAPEUTICS PIPELINE DRUGS ANALYTICS
    • VACCINES PIPELINE ANALYTICS
    • PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
  • 5.4. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION
  • 5.5. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • 5.6. PIPELINE DRUGS ANALYTICS BY TARGET
  • 5.7. PIPELINE DRUGS ANALYTICS OF REPURPOSED DRUGS, NEW BIOLOGICAL ENTITIES,NEW CHEMICAL ENTITIES
  • 5.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

CHAPTER 06: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

  • 6.1. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 6.2. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES
  • 6.3. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

CHAPTER 07: ESTIMATED APPROVAL TIMELINES OF COVID-19 PIPELINE DRUGS

  • 7.1. METHODOLOGY
  • 7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

CHAPTER 8: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

  • 8.1: EXTERNAL DEPENDENCIES
  • 8.2: PIPELINE PORTFOLIO
  • 8.3: EXPECTED MARKET ENTRIES
  • 8.4: PATENTS AND EXCLUSIVITY
  • 8.5: MARKETING DYNAMICS AND PARTNERING
  • 8.6: ACHIEVEMENTS OF SPECIAL REGULATORIES
  • 8.7: COMPANY DEVELOPMENTS

CHAPTER 9: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 9.1: EMERGING COMPANIES
    • 9.1.1 EMERGING COMPANY PROFILES
      • 9.1.1.1. INOVIO PHARMACEUTICALS, INC.
      • 9.1.1.2. NOVAVAX, INC.
      • 9.1.1.3. DYNAVAX TECHNOLOGIES CORPORATION
      • 9.1.1.4. SICHUAN CLOVER BIOPHARMACEUTICALS, INC.
      • 9.1.1.5. HEAT BIOLOGICS, INC.
      • 9.1.1.6. PREDICTIVE ONCOLOGY
      • 9.1.1.7. SORRENTO THERAPEUTICS, INC.
      • 9.1.1.8. VAXART, INC.
      • 9.1.1.9. ENTOS PHARMACEUTICALS
      • 9.1.1.10. ATHERSYS, INC.
      • 9.1.1.11. IMMUNIC THERAPEUTICS, INC.

LIST OF TABLES

  • TABLE 01: COVID-19 REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: COLLABORATION DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 03: FINANCING DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 04: LICENSING DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 05: MERGER AND ACQUISITION DEALS IN COVID-19 THERAPEUTIC AREA
  • TABLE 06: PATENTS FILED BY INOVIO PHARMACEUTICALS
  • TABLE 07: PATENTS AND PATENT APPLICATIONS FILED BY ENTOS PHARMACEUTICALS
  • TABLE 08: CORONAVIRUS DISEASE 2019 (COVID-19) PHASE III PIPELINE MOLECULES
  • TABLE 09: CORONAVIRUS DISEASE 2019 (COVID-19) PHASE II/III AND PHASE IIB/III PIPELINE MOLECULES
  • TABLE 10: CORONAVIRUS DISEASE 2019 (COVID-19) PHASE II PIPELINE MOLECULES
  • TABLE 11: CORONAVIRUS DISEASE 2019 (COVID-19) PHASE I/II PIPELINE MOLECULES
  • TABLE 12: PHASE I PIPELINE MOLECULES FOR THE TREATMENT OF COVID-19
  • TABLE 13: PRECLINICAL MOLECULES FOR THE TREATMENT OF COVID-19
  • TABLE 14: EARLY RESEARCH AND DEVELOPMENT MOLECULES FOR THE TREATMENT OF COVID-19
  • TABLE 15: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION
  • TABLE 16: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION
  • TABLE 17: LIST OF ANTIVIRAL THERAPEUTICS UNDERDEVELOPMENT
  • TABLE 18: LIST OF ANTIBODY-BASED THERAPEUTICS UNDER DEVELOPMENT
  • TABLE 19: LIST OF SMALL MOLECULE THERAPEUTICS UNDER DEVELOPMENT
  • TABLE 20: LIST OF VACCINES UNDER DEVELOPMENT
  • TABLE 21: LIST OF CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 22: LIST OF NON-CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 23: LIST OF COMPANIES DEVELOPING BIOLOGICAL ANIBODY BASED THERAPEUTICS
  • TABLE 24: LIST OF CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
  • TABLE 25: LIST OF NON-CLINICAL STAGE PIPELINE MOLECULES WITH THEIR MOLECULAR TARGETS
  • TABLE 26: NON-CLINICAL PIPELINE DRUGS VS REPURPOSED DRUGS, NBES AND NCES
  • TABLE 27: COVID-19 PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • TABLE 28: REGION WISE STATISTICS, COMPANY COUNT WITH COUNT OF COVID-19 PIPELINE CANDIDATES
  • TABLE 29: MILESTONES OF FAVIPIRAVIR
  • TABLE 30: MILESTONES OF REMDESIVIR
  • TABLE 31: MILESTONES OF ACTEMRA
  • TABLE 32: MILESTONES OF RUXOLITINIB
  • TABLE 33: MILESTONES OF CD24FC
  • TABLE 34: MILESTONES OF LERONLIMAB
  • TABLE 35: MILESTONES OF KEVZARA
  • TABLE 36: MILESTONES OF AVIPTADIL (RLF-100)
  • TABLE 37: MILESTONES OF MULTISTEM THERAPY
  • TABLE 38: MILESTONES OF REMESTEMCEL-L
  • TABLE 39: MILESTONES OF IMU-838
  • TABLE 40: MILESTONES OF ABX464
  • TABLE 41: MILESTONES OF POLYOXIDONIUM
  • TABLE 42: GERVANORA ESTIMATED APPROVAL TIMELINES V/S ACTUAL APPROVAL DATE
  • TABLE 43: THERAPEUTIC DRUGS (PHASE III) ESTIMATED APPROVAL TIMELINES
  • TABLE 44: VACCINES ESTIMATED APPROVAL TIMELINES
  • TABLE 45: PIPELINE ASSETS OF INOVIO WITH RESPECT TO HPV-TARGETED TREATMENTS
  • TABLE 46: PIPELINE ASSETS OF INOVIO WITH RESPECT TO IMMUNO-ONCOLOGY
  • TABLE 47: PIPELINE ASSETS OF INOVIO WITH RESPECT TO INFECTIOUS DISEASE
  • TABLE 48: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF INOVIO
  • TABLE 49: PIPELINE ASSETS OF NOVAVAX
  • TABLE 50: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF NOVAVAX
  • TABLE 51: PRESENTTION AND EVENTS OF NOVAVAX
  • TABLE 52: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF DYNAVAX
  • TABLE 53: PIPELINE ASSETS OF CLOVER
  • TABLE 54: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF CLOVER
  • TABLE 55: PIPELINE ASSETS OF HEAT BIOLOGICS
  • TABLE 56: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF HEAT BIOLOGICS
  • TABLE 57: PRESENTATION AND EVENTS OF HEAT BIOLOGICS
  • TABLE 58: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF PREDICTIVE ONCOLOGY
  • TABLE 59: PIPELINE ASSETS OF SORRENTO WITH RESPECT TO IMMUNO-ONCOLOGY
  • TABLE 60: PIPELINE ASSETS OF SORRENTO WITH RESPECT TO PAIN
  • TABLE 61: PIPELINE ASSETS OF SORRENTO WITH RESPECT TO LYMPHATIC DELIVERY
  • TABLE 62: PIPELINE ASSETS OF SORRENTO WITH RESPECT TO COVID-19
  • TABLE 63: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF SORRENTO
  • TABLE 64: PIPELINE ASSETS OF VAXART
  • TABLE 65: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF VAXART
  • TABLE 66: PATENTS AND PATENT APPLICATIONS FILED BY ENTOS PHARMACEUTICALS
  • TABLE 67: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF ENTOS PHARMACEUTICALS
  • TABLE 68: PIPELINE ASSETS OF ATHERSYS
  • TABLE 69: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENTS OF ATHERSYS
  • TABLE 70: PRESENTATIONS AND EVENTS OF ATHERSYS
  • TABLE 71: PIPELINE ASSETS OF IMMUNIC THERAPEUTICS
  • TABLE 72: RESEARCH AND DEVELOPMENT ACTIVITIES AND RECENT DEVELOPMENT OF IMMUNIC THERAPEUTICS

LIST OF FIGURES

  • FIGURE 01: KEY EVENTS IN THE COVID-19 COMPETITIVE SPACE
  • FIGURE 02: GLOBAL INFECTED POPULATION FROM LAST FIVE MONTHS
  • FIGURE 03: RUSSIA, SPAIN, UK, ITALY, GERMANY AND FRANCE'S COVID-19 INFECTED POPULATION FROM LAST FIVE MONTHS
  • FIGURE 04: COVID-19 DEAL ANALYTICS BY DEAL TYPE
  • FIGURE 05: INIDIVIDUAL DEAL STATISTICS FOR COLLABORATION DEALS
  • FIGURE 06: INIDIVIDUAL DEAL STATISTICS FOR FUNDING DEALS
  • FIGURE 07: INIDIVIDUAL DEAL STATISTICS FOR LICENSING DEALS
  • FIGURE 08: COVID-19 DEAL ANALYTICS BY DEAL FREQUENCY
  • FIGURE 09: DEALS ANALYTICS BY ACTIVE PLAYERS
  • FIGURE 10: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
  • FIGURE 11: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
  • FIGURE 12: COVID-19 DRUGS PIPELINE ANALYTICS BY ROA
  • FIGURE 13: COVID-19 DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA
  • FIGURE 14: PARENTERAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 15: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 16: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
  • FIGURE 17: LIST OF COMPANIES WITH RESPECT TO THE DRUG CLASSES
  • FIGURE 18: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 19: COVID-19 PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES
  • FIGURE 20: COVID-19 PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE
  • FIGURE 21: COVID-19 PIPELINE DRUGS ANALYTICS BY REPURPOSED DRUGS, NBES AND NCES
  • FIGURE 22: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON COVID-19
  • FIGURE 23: COUNT OF COMPANIES WITH RESPECT TO THE THERAPY TYPE
  • FIGURE 24: CLINICAL EFFICACY OUTCOMES AT DAY 14 OF REMDESIVIR
  • FIGURE 25: REDUCTION IN C-REACTIVE PROTEIN IN KEVZARA CLINICAL TRIAL
  • FIGURE 26: PHASE III ANTICIPATED DRUG APPROVALS
  • FIGURE 27: RESEARCH AND DEVELOPMENT EXPENSES OF TOP 3 COMPANIES IN $M
  • FIGURE 28: PIPELINE PORTFOLIO WITH (NUMBER OF MOLECULES)
  • FIGURE 29: EXPECTED MARKET ENTRY WITH RESPECT TO DRUG CANDIDATES TREATING COVID-19
  • FIGURE 30: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO COVID-19 TREATMENTS
  • FIGURE 31: RANKING TOP 6 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
Back to Top